| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/PR901188E |
| P8608 | Fatcat ID | release_avwecl3bsfcbxbstqsinyxffei |
| P698 | PubMed publication ID | 20337404 |
| P5875 | ResearchGate publication ID | 42587534 |
| P50 | author | Jeremy K. Nicholson | Q18720163 |
| Elaine Holmes | Q28469525 | ||
| Kirill Veselkov | Q50618679 | ||
| John C Lindon | Q88332831 | ||
| Ivan Kok Seng Yap | Q92697715 | ||
| P2093 | author name string | Manya Angley | |
| P2860 | cites work | Recursive segment-wise peak alignment of biological (1)h NMR spectra for improved metabolic biomarker recovery. | Q48460973 |
| P433 | issue | 6 | |
| P921 | main subject | sibling | Q31184 |
| autism | Q38404 | ||
| autistic child | Q110955678 | ||
| P304 | page(s) | 2996-3004 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Journal of Proteome Research | Q3186939 |
| P1476 | title | Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls | |
| P478 | volume | 9 |
| Q37980065 | 1H NMR-based metabonomic applications to decipher gut microbial metabolic influence on mammalian health |
| Q50663896 | 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. |
| Q60305462 | A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses |
| Q37948828 | A review of candidate urinary biomarkers for autism spectrum disorder. |
| Q93167649 | Age-specific urinary metabolite signatures and functions in patients with major depressive disorder |
| Q35665025 | Alterations in the Vaginal Microbiome by Maternal Stress Are Associated With Metabolic Reprogramming of the Offspring Gut and Brain |
| Q61809062 | Altered Urinary Amino Acids in Children With Autism Spectrum Disorders |
| Q34994418 | Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study |
| Q59263464 | Analysis of amino acids in autism spectrum disorders |
| Q59263469 | Analytical methods used in autism spectrum disorders |
| Q34428337 | Autism and nutrition: the role of the gut-brain axis |
| Q42790242 | Autism: metabolism, mitochondria, and the microbiome |
| Q37493061 | Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly |
| Q92898092 | Biomarkers in Autism Spectrum Disorder: Challenges, Advances, and the Need for Biomarkers of Relevance to Public Health |
| Q38149740 | Biomarkers in autism spectrum disorder: the old and the new. |
| Q38816381 | Body fluid levels of neuroactive amino acids in autism spectrum disorders: a review of the literature. |
| Q97419518 | Bridging the Gap Between Physical Health and Autism Spectrum Disorder |
| Q36620171 | Clinical metabolomics paves the way towards future healthcare strategies |
| Q50306889 | Combined 1H-NMR and 1H-13C HSQC-NMR to improve urinary screening in autism spectrum disorders. |
| Q37733240 | Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. |
| Q93261022 | Connection between gut microbiome and brain development in preterm infants |
| Q58572427 | Could nodding syndrome in Northern Uganda be a form of autism spectrum disorder? an observational study design |
| Q28680718 | Current progress and challenges in the search for autism biomarkers |
| Q21198692 | Decreased tryptophan metabolism in patients with autism spectrum disorders |
| Q37102857 | Development of an integrated metabolomic profiling approach for infectious diseases research |
| Q35099056 | Does our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics |
| Q42106652 | Dog bites man or man bites dog? The enigma of the amino acid conjugations |
| Q36702899 | Early infant exposure to excess multivitamin: a risk factor for autism? |
| Q50307384 | Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. |
| Q27024805 | Environment, dysbiosis, immunity and sex-specific susceptibility: a translational hypothesis for regressive autism pathogenesis |
| Q50301433 | GC-MS-based urine metabolic profiling of autism spectrum disorders. |
| Q35142420 | Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders |
| Q36245131 | Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations. |
| Q56672658 | Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases |
| Q39018584 | Gut Microbiota and Autism: Key Concepts and Findings |
| Q47093226 | High resolution metabolomic analysis of ASD human brain uncovers novel biomarkers of disease |
| Q89878939 | Higher Levels of Low Molecular Weight Sulfur Compounds and Homocysteine Thiolactone in the Urine of Autistic Children |
| Q28085629 | Human Microbiome: When a Friend Becomes an Enemy |
| Q36508139 | Identification and validation of urinary metabolite biomarkers for major depressive disorder |
| Q55091656 | Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. |
| Q35907785 | Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis |
| Q33827416 | Immunostimulation in the era of the metagenome |
| Q47576796 | In search of biomarkers for autism: scientific, social and ethical challenges |
| Q28587344 | In vitro fermentation of B-GOS: impact on faecal bacterial populations and metabolic activity in autistic and non-autistic children |
| Q52311705 | Indole, a Signaling Molecule Produced by the Gut Microbiota, Negatively Impacts Emotional Behaviors in Rats. |
| Q31142266 | Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities |
| Q51639262 | Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. |
| Q35271721 | Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism |
| Q33760402 | MIRA: mutual information-based reporter algorithm for metabolic networks |
| Q30885784 | Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions |
| Q34252098 | Metabolic differences underlying two distinct rat urinary phenotypes, a suggested role for gut microbial metabolism of phenylalanine and a possible connection to autism |
| Q36903783 | Metabolic phenotyping and systems biology approaches to understanding neurological disorders |
| Q38059779 | Metabolic phenotyping in clinical and surgical environments |
| Q91535393 | Metabolome signature of autism in the human prefrontal cortex |
| Q35051204 | Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study |
| Q90467658 | Metabolomics analysis of children with autism, idiopathic-developmental delays, and Down syndrome |
| Q57131341 | Metabolomics and Isotope Tracing |
| Q102379382 | Metabolomics and psychological features in fibromyalgia and electromagnetic sensitivity |
| Q28544817 | Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children |
| Q46531633 | Metabolomics of autism spectrum disorders: early insights regarding mammalian-microbial cometabolites. |
| Q61986980 | Metabonomic approaches to nutrient metabolism and future molecular nutrition |
| Q38870788 | Metabonomic investigation of human Schistosoma mansoni infection |
| Q34519313 | Microbial ecosystems therapeutics: a new paradigm in medicine? |
| Q38793435 | Microbiome and nutrition in autism spectrum disorder: current knowledge and research needs |
| Q24630557 | Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis |
| Q26749210 | Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases |
| Q50304998 | Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. |
| Q28730781 | Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra |
| Q35585761 | Novel systems modeling methodology in comparative microbial metabolomics: identifying key enzymes and metabolites implicated in autism spectrum disorders |
| Q47110549 | Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer |
| Q35551472 | Nutrigenomics and personalized diets: What will they mean for food? |
| Q35102732 | Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity |
| Q28390150 | Nutritional lipidomics: molecular metabolism, analytics, and diagnostics |
| Q94560655 | Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by Mycobacterium tuberculosis |
| Q37822760 | Pharmacometabonomics as an effector for personalized medicine. |
| Q35816838 | Potential of serum metabolites for diagnosing post-stroke cognitive impairment |
| Q36395466 | Potential serum biomarkers from a metabolomics study of autism |
| Q58591209 | Predictive Role of Urinary Metabolic Profile for Abnormal MRI Score in Preterm Neonates |
| Q34343570 | Prenatal and perinatal analgesic exposure and autism: an ecological link |
| Q27691431 | RETRACTED: Gut microbiota and pediatric disease. |
| Q34757521 | Sex-specific urinary biomarkers for diagnosing bipolar disorder |
| Q37106022 | Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders |
| Q28083342 | Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review |
| Q37065375 | The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder? |
| Q57151369 | The Gut Microbiota and Dysbiosis in Autism Spectrum Disorders |
| Q26797273 | The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children |
| Q64948229 | The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder. |
| Q36564707 | The intestinal microbiome, probiotics and prebiotics in neurogastroenterology |
| Q48256154 | The microbiota and the gut-brain axis: insights from the temporal and spatial mucosal alterations during colonisation of the germfree mouse intestine. |
| Q35155407 | The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? |
| Q35114569 | The mind-body-microbial continuum |
| Q35494817 | The potential role of probiotics in the management of childhood autism spectrum disorders. |
| Q36027303 | The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis |
| Q37729525 | The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases |
| Q28304749 | The role of microbiome in central nervous system disorders |
| Q48122460 | The urinary 1 H-NMR metabolomics profile of an italian autistic children population and their unaffected siblings. |
| Q50303972 | The urinary metabolomics profile of an Italian autistic children population and their unaffected siblings. |
| Q38016806 | Therapeutic modulation of microbiota-host metabolic interactions. |
| Q38055197 | Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs |
| Q58040335 | UPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers |
| Q37661051 | Unravelling the metabolic impact of SBS-associated microbial dysbiosis: Insights from the piglet short bowel syndrome model |
| Q90264503 | Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future Directions |
| Q26769944 | Urinary Biomarkers of Brain Diseases |
| Q30277666 | Urinary N-methylnicotinamide and β-aminoisobutyric acid predict catch-up growth in undernourished Brazilian children |
| Q34942215 | Urinary amino acid alterations in 3-year-old children with neurodevelopmental effects due to perinatal dioxin exposure in Vietnam: a nested case-control study for neurobiomarker discovery |
| Q57155162 | Urinary biomarker panel for diagnosing patients with depression and anxiety disorders |
| Q42363874 | Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism. |
| Q35645024 | Urinary metabonomics for diagnosis of depression in hepatitis B virus-infected patients |
| Q50312706 | Urinary p-cresol is elevated in small children with severe autism spectrum disorder. |
| Q50305926 | Urinary p-cresol is elevated in young French children with autism spectrum disorder: a replication study. |
| Q34420046 | Use of solid-phase microextraction coupled to gas chromatography-mass spectrometry for determination of urinary volatile organic compounds in autistic children compared with healthy controls. |
Search more.